| Literature DB >> 33747345 |
Ghulam Md Ashraf1,2, Mahmoud Ahmed Ebada3,4, Mohd Suhail1,2, Ashraf Ali5, Md Sahab Uddin6,7, Anwar L Bilgrami8,9, Asma Perveen10, Amjad Husain10,11,12, Mohd Tarique13, Abdul Hafeez14, Athanasios Alexiou15,16, Ausaf Ahmad17, Rajnish Kumar17, Naheed Banu18, Agnieszka Najda19, Amany A Sayed20, Ghadeer M Albadrani21, Mohamed M Abdel-Daim22, Ilaria Peluso23, George E Barreto24,25.
Abstract
The brain is a sexually dimorphic organ that implies different functions and structures depending on sex. Current pharmacological approaches against different neurological diseases act distinctly in male and female brains. In all neurodegenerative diseases, including Alzheimer's disease (AD), sex-related outcomes regarding pathogenesis, prevalence, and response to treatments indicate that sex differences are important for precise diagnosis and therapeutic strategy. Pathogenesis of AD includes vascular dementia, and in most cases, this is accompanied by metabolic complications with similar features as those assembled in diabetes. This review discusses how AD-associated dementia and diabetes affect cognition in relation to sex difference, as both diseases share similar pathological mechanisms. We highlight potential protective strategies to mitigate amyloid-beta (Aβ) pathogenesis, emphasizing how these drugs act in the male and female brains.Entities:
Mesh：
Year: 2021 PMID： 33747345 PMCID： PMC7960032 DOI： 10.1155/2021/4572471
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN： 1942-0994 Impact factor: 6.543